Germline editing debate

Claim: Expanding newborn genetic screening to report adult-onset disease risks should not be made routine under current conditions, though the core panel that catches treatable childhood conditions should continue.\n\nEvidence 1: Every baby born in the United States already gets a heel-stick blood test, and the standard panel screens for conditions like PKU and sickle cell disease that can be treated in early childhood if caught right away.\n\nEvidence 2: When pilot programs added whole-genome sequencing that also flagged adult-onset risks, such as certain cancer or heart-disease genes, they surfaced findings the child could not act on for decades and that the newborn obviously could not consent to learning.\n\nReasoning: Because the newborn cannot consent, and because an adult-onset result becomes part of that person's record for life whether or not they ever wanted to know it, the lasting burden of unwanted information outweighs the benefit when the child cannot act on it for years. Screening that leads to treatment in childhood clears that bar, but screening for risks the child cannot use should wait until safeguards and the person's own choice are in place.\n\nReflection: One counterargument is that flagging an adult-onset risk at birth could let a family plan early and catch a disease sooner. I weighed it seriously, but kept my claim, because the newborn never chose to carry that knowledge, and a benefit to the family does not close the gap that the child never consented.